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Abstract 
To determine viral subtypes and resistance mutations to antiretroviral treatment (ART) in 
untreated HIV-1 acutely infected subjects from Southwest Switzerland. Clinical samples were 
obtained from the HIV primary infection cohort from Lausanne. Briefly, pol gene was 
amplified by nested PCR and sequenced to generate a 1 kb sequence spanning protease and 
reverse transcriptase key protein regions. Nucleotide sequences were used to assess viral 
genotype and ART resistance mutations. Blood specimens and medical information were 
obtained from 30 patients. Main viral subtypes corresponded to clade B, CRF02_AG, and F1. 
Resistant mutations to PIs consisted of L10V and accessory mutations 16E and 60E present in 
all F1 clades. The NNRTI major resistant mutation 103N was detected in all F1 viruses and in 
other 2 clades. Additionally, we identified F1 sequences from other 6 HIV infected and 
untreated individuals from Southwest Switzerland, harboring nucleotide motifs and resistance 
mutations to ART as observed in the F1 strains from the cohort. These data reveal a high 
transmission rate (16.6%) for NNRTI resistant mutation 103N in a cohort of HIV acute 
infection. Three of the 5 resistant strains were F1 clades closely related to other F1 isolates 
from HIV-1 infection untreated patients also coming from Southwest Switzerland. Overall, 
we provide strong evidence towards an HIV-1 resistant transmission network in Southwest 
Switzerland. These findings have relevant implications for the local molecular mapping of 
HIV-1 and future ART surveillance studies in the region. 
Background 
In Switzerland, prevalence of transmitted HIV-1 single drug resistance is 7.7% among 
individuals within the first year after seroconversion and rarely involves dual or triple-class 
resistance [1]. Additionally, another survey from the Swiss HIV Cohort Study (SHCS) which 
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also assessed HIV recent infection in neighbouring France found a higher prevalence of 
transmitted resistance among subtype B carriers as compared to non-B HIV infections [1,2].  
Thereby, the objective of this investigation was to determine viral subtypes and resistance 
mutations to antiretroviral treatment in untreated HIV-1 acutely infected subjects from 
Southwest Switzerland.   
Patients and Methods 
Clinical samples were obtained from an ongoing HIV primary infection clinical trial taking 
place at the Vaccine and Immunotherapy Center from Lausanne since 1998. This research 
protocol was approved by the Research Ethics Committee from the Faculty of Biology and 
Medicine of the University of Lausanne. Individuals enrolled in the study signed the informed 
consent and met the following criteria: 2-3 weeks from onset of HIV primary infection 
symptoms, incomplete seroconversion status verified by western blot and a positive p24 
antigen (Elecsys HIV Antigen Immunoassay, Roche Diagnostics, Basel, Switzerland). Whole 
blood EDTA samples collected at baseline were centrifuged to obtain plasma and extract viral 
RNA with the Qiagen QIAamp Viral RNA Mini Kit. Then pol gene was amplified through a 
nested polymerase chain reaction (PCR) and sequenced to generate a 1 to 1.5kb fragment. The 
genotyping algorithm from Virco (VirtualPhenotypeTM,Beerse, Belgium) was used in most 
cases. Alternatively, genotyping assessment was completed in a subset of samples by an in-
house nested PCR protocol using amplification and sequencing primers previously described 
by Eyer-Silva and col. [3]. Briefly, DNA samples (± 1μg) were amplified in a GeneAmp 9700 
PCR system (Applied Biosystems, Foster City, CA) to obtain a 1kb fragment spanning 
protease and reverse transcriptase regions (location  from start of HXB2 genome 2250 → 
3250). GeneAmp XL PCR kit (Applied Biosystems) was used to improve PCR performance 
and optimize the yield of long amplified products.  A hot start consisting of 80°C (5 min), 
followed by 25°C (3 min) was initially performed on the lower first round mix sealed with 
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AmpliWax (Applied Biosystems). After, first round PCR was completed with an upper mix 
containing rTth DNA polymerase XL and DNA templates under the following thermocycling 
conditions: 94°C (1min) followed by 28 cycles with 94°C (15 s) and annealing at 60°C (10 
min), continued by final extension at 72°C (10 min). Next, a nested PCR run using AmpliTaq 
Gold DNA Polymerase Kit (Roche) took place as follows: 1 cycle with 95°C (3 min), 55°C (1 
min) and 72°C (1 min) continued by 35 cycles with 95°C (1 min), 55°C (45 s) and 72°C  (1 
min) plus a final extension step of 10 min at 72°C. Sequencing reaction mixtures were 
assembled with BigDye Terminator v.3.0 Cycle kit (Applied Biosystems) and loaded to an 
ABI310 Genetic Analyzer. Nucleotide sequences were edited with BioEdit 7.0 and aligned by 
CLUSTAL X 2.0 alignment program with known reference strains of group M and circulating 
recombinant forms (CRFs) sequences pooled from the HIV-1 gene database  (http://hiv-web-
lanl.gov/).  
Viral subtype was determined by Phylip DNADIST trees and bootstrap analysis.  
Drug resistance mutations were examined using the 2009 Stanford HIV drug resistance list 
(http://hivbd.stanford.edu). 
Viral load was initially assessed by COBAS Amplicor HIV-1 Monitor version 1.5 and 
replaced later by real-time PCR (COBAS AmpliPrep/COBAS TaqMan version 1.0 Roche). 
Also CD4+ T cell counts were determined by multiparameter flow cytometry. 
Results  
Isolates were collected from 30 individuals (29 men and 1 woman) assigned as primary HIV 
infection one through thirty (PHI-1 to 30), respectively. All subjects were at incomplete 
western blot seroconversion window with a mean viral load of 7.3 Log HIV-1 RNA  
copies/mL (range, 4 to 8) and mean CD4+ T cell count of 428 cells/mm
3 
(range, 122 to 965). 
Risk transmission groups consisted of men having sex with men (66.6%), heterosexual 
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intercourses (20%), IV drug users (10%) and one case (3.3%) of undefined transmission 
route.  
Viral subtype assignments corresponded to clade B (n=15), CRF02_AG (n=3), F1 (n=3), 
CRF11-like (n=2), CRF01_AE (n=2), G (n=2), subtype D (n=2) and one untyped recombinant 
isolate PHI-16 (figure 1). To better assess CRF11-like sequences (PHI-11 and 25) and PHI-
16, we plotted this 3 pol sequences to a deduced  alignment consisting of clades A1, J, 
CRF11_cpx  and D to determine similarity boundaries of PHI-16, after  testing the consensus 
alignment provided in NCBI HIV-1 genotyping tool (http://www.ncbi.nlm.nih.gov/projects/   
genotyping/formpagex.cgi). This analysis emphazised a high nucleotide similarity among 
PHI-11 and 25 as well as their divergency to CRF11_cpx reference sequences. Additionally, 
it revealed a mosaic clade composition for PHI-16 sequence consisting of CRF11/D with 75% 
similarity threshold and to A1 with a lower threshold (figure 2). Both patients harboring 
CRF11-like isolates were among the group of IV drug users, therefore we cannot exclude that 
they might carry the CRF11-like variant from western Switzerland as previously reported 
among IV drug users [4]. However, neither signatures nor complete genome information is 
availible to validate this assumption. Finally, patient PHI-16 reported heterosexual 
intercourses with different partners and also harbored a different J-like recombinant as seen 
for PHI-11 and 25.  
No major resistant mutations to PIs were detected. However minor mutation L10V, and 
accessory mutations 16E and 60E were found in all F1 clades (PHI-2; 3 and 22).  
The RT amino acid sequences analysis revealed NNRTI major resistant mutation 103N in all 
clade F1 viruses. Also 103N was detected in one B clade (PHI-29) and in the D strain from 
the cohort (PHI-15). Moreover, PHI-15 also harbored resistance mutations to NRTIs as TAMs 
41L and 215Y (table 1). 
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To determine whether these PHI-F1 sequences were indeed a founder effect or a hint towards 
a transmission network we extended the phylogenetic analysis to other HIV-1 F1 infections 
genotyped at the routine laboratories from Lausanne (n=11) and Geneva (n=13) during 1999 
to 2007. A group of 24 partial pol sequences were analyzed. Sequences obtained from Geneva 
consisted of two separated fragments spanning reverse transcriptase and protease, 
respectively.  
The resulting subtype F1 nucleotide alignment was used to determine ratios of synonymous to 
non-synonymous base substitutions (ds/dn) with Los Alamos HIV database website tool 
SNAP [5] and plotted with Highlighter (www.hiv.lanl.gov) to illustrate codon-aligned 
mutations by using sequence PHI-3 as master reference (figure 3). Both SNAP statistical 
output and codon-aligned sequences plot distinguished two clusters of sequences with a 
strong homology to PHI-3 viral sequence and ds/dn ratios of 11.12  and 14.51, respectively. 
Cluster 1 harbored three new sequences from Lausanne (Lau0623/0567/0575) and cluster 2 
three sequences from Geneva (Gen0552/0558/0641). Only one sequence (Gen0552) showed 
no non-synonymous base substitution to PHI-3. Collectively, the remaining F1 sequences 
from the alignment had a ds/dn value of 7, 1.5 to 2 times smaller as observed for cluster 1 and 
2.  
Then we checked for the presence of drug resistance related mutations and polymorphisms 
previously found in the PHI-F1 sequences among the other Lausanne (n=3) and Geneva (n=3) 
members. Interestingly, 103N was found in 5/6 sequences and 10V in the entire set. 
Additionally, all other accessory mutations were confirmed too.  
Discussion 
Resistance mutations to NNRTI 103N, 181C and 184V/I were previously reported as minority 
quasispecies in patients from Southwest Switzerland with early therapy failure using allele-
specific real-time PCR in pretreatment plasma samples but the study was limited to 4 clinical 
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cases [6]. However, the Swiss HIV Cohort Study (SHCS) reported recently an increased rate 
of NNRTI resistance (3.5%) in newly diagnosed HIV infected individuals, underscoring 103N 
substitution as the second most common mutation from this drug class with a rate of 37% 
among all individuals harboring NNRTI resistance [7].  All together these reports provide 
evidence to the continuous and increasing transmission of 103N mutation in the local 
epidemic.  
The 9-mer K103N mutant peptide 101 -109 KKNKSVTVL has been proven to display CTL 
activity in chronic HIV patients exposed to NNRTI and harboring HLA-A23 allele [8]. 
However, according to the HLA typing performed with nucleotide sequencing in the routine 
laboratory from the Immunology Service of the Centre Hospitalier Universitaire Vaudois, 
none of the individuals infected with HIV F1 subtype from the dataset carried A23 allele.  As 
for protease accessory mutations found in the PHI-F1 cluster, they involve amino acid 
positions in known human HIV CTL epitope lengths 3-11; 7-16; 57-66; 70-77 and 77-84, as 
listed in the HIV molecular immunology database from Los Alamos 
(http://www.hiv.lanl.gov). If indeed, protease mutations (10V,16E, 60E, 77I) detected in the 
PHI-F1 cluster have been previously reported among HIV-1 untreated patients carrying 
subtype F, there is only evidence for 103N mutation as naturally occurring in F1 clade [9] nor 
associated to HLA-driven selection [10].  
Moreover, the extended analysis of the other HIV-1  F1 sequences obtained from untreated 
and non related infected individuals during the same period in Geneva and Lausanne revealed 
the presence of two clusters with tightly related sequences as defined by nucleotide motifs and 
drug resistance patterns.  
Conclusions 
This study has determined a high transmission rate (16.6%) for NNRTI resistant mutation 
103N in a cohort of acute HIV infection from Lausanne due to 50% of non-B clades. Four of 
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the 5 men harboring F1 or D clade 103N resistant viruses were diagnosed during 2005 and 
one later case corresponds to a B clade infection from 2007. They all contracted HIV 
infection through unprotected sexual intercourse with occasional sexual partners. Three of 
these 5 men (two MSM and one heterosexual man) carried a highly homogeneous F1 clade 
distinct from previously reported F1 local sequences. Despite the small number of acutely 
infected patients considered in this study and the multiple clades detected, we provide strong 
epidemiological and molecular evidence towards an HIV-1 subtype F1 resistant strain 
transmission in Southwest Switzerland.  
Moreover, the presence of 103N mutation in newly HIV-1 B and non-B clade infections 
reveals cross-clade antiretroviral resistance transmission (ART) at the local epidemic level. 
These findings have relevant implications for the local molecular mapping of HIV-1 and 
future ART surveillance studies in the region. 
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Figure 1 
Neighbor-joining tree of HIV-1 sequences from the Lausanne primary 
infection cohort with group M and CRF reference sequences pulled 
from the Los Alamos HIV database 
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Nucleotide alignment of 1047bp relaltive position in HXB2 gag 1464 → 1503 
and  pol 169 → 1215.  Bootstrap values greater than 75% are shown. 
Figure 2 
Similaritiy plot of HIV-1 pol genotype obtained from the primary infection 
Lausanne cohort participant PHI-16 compared to CRF11-like sequences 
from the cohort and reference sequences  
Reference sequences consisted of CRF11_cpx AF492623/AF492624, clade A1 
AF004885/AF069670, subtype D M272323/U88822 and clade J AF082394/ AF082395. 
The upper layer from the genotype bar was estimated with 75% similaritiy threshold to 
CRF11_cpx and D sequences. Whereas the two lower ones including A1 sequences were 
calculated at 65% similarity threshold. This analysis was inferred with the genotyping 
advanced tool  in: http://www.ncbi.nlm.nih.gov/projects/genotyping/formpagex.cgi 
Reverse Transcriptase 582bp alignment. Nucleotide relative position in HXB2 92 → 674. 
SplitsTree neighbor-net distance hamming method with Fit=95.86. Initials refer to 
sequences reported origen being “PHI” the Primary HIV Infection cohort from Lausanne, 
“Lau” Lausanne, “Gen” Geneva, “FR” France, “R” Romania, “IT” Italy and “BZ; BR” Brazil. 
 
Figure 3 
Network analysis of HIV-1 clade F1 sequences from Southwest Switzerland  
and reference sequences pulled from the Los Alamos HIV database 
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Amino acid relative position to protein regions in HXB2: protease 1 → 99   followed by reverse transcriptase 1 → 
220.  Black columns show common polymorphic positions; gray highlights similar aa substitutions; “X” means 
codon translations containing IUPAC character in a silent position whereas “X ” refers to other positions; “          “ 
indicates  related drug resistance mutations; “-” stands for gaps and  “*”  for stop codon. Gene Cutter Sequence 
Alignment  and Protein extraction tool (http://www.hiv.lanl.gov). 
Figure 4 
